Stockreport

Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis [Yahoo! Finance]

Cardiol Therapeutics Inc. - Class A Common Shares  (CRDL) 
PDF clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease [Read more]